Immutrin secures £19.5m Series A to advance antibody therapies for amyloidosis

Developing antibody therapies to reverse amyloidosis is the core mission of Cambridge-based Immutrin, which has just closed a significant funding round. The biotechnology firm secured an estimated £19.5m in its latest Series A investment. This capital injection follows a previous Series A round of £3.7m completed in February.

Founded in 2019, Immutrin focuses on the systematic study of biological systems to modify products for specific medical applications. Its primary work involves creating next-generation antibody treatments to deplete systemic amyloid deposits. The company lead asset is specifically designed for the treatment of ATTR cardiomyopathy, a progressive form of amyloidosis. This therapy utilizes a unique mechanism of action to selectively and exclusively remove established amyloid fibrils.

The recent £19.5m raise (allotted in April and filed in May) represents a substantial increase in scale compared to the company earlier financing. Immutrin previously raised £1.2m in a September 2024 seed round. Other prior funding includes a £950k seed round in April 2023, two seed tranches in February 2023 totaling £950k, and a £300k seed round in March 2022. The company first recorded funding was a £300k raise in December 2019.

Financial metrics for the year ending 31 August 2025 show that Immutrin recorded a £1m loss. While the company formal accounts for that period listed six employees, more recent data indicates the workforce has expanded to 12 people. The company remains headquartered in Cambridge, where it continues its research and experimental development. Total capital raised by the firm since its incorporation now stands at £26.9m.